Dr. Fernand Labrie

Dr. Fernand Labrie

Dr. Fernand Labrie is one of the most accomplished researchers in the international scientific community. He has received a series of awards attesting his accomplishments and notoriety. 

Academic Background

After obtaining his MD followed by his PhD degree in endocrinology at Laval University, Dr. Fernand Labrie pursued his postdoctoral research training at the University of Cambridge, United Kingdom, first in the Laboratory of Professor Asher Korner in the Department of Biochemistry and then, in the Laboratory of Molecular Biology with Professor Frederick Sanger, twice Nobel laureate in medicine.


Indeed, Dr. Labrie's scientific advances and discoveries are described in more than 1330 scientific publications and have been cited more than 50,000 times. Dr. Labrie is the most cited Canadian scientist among all disciplines in the international literature. Among a long series of awards, he received the King Faisal International Prize in medicine for his discoveries in prostate cancer as well as the Hoffenberg International Award from the Society for Endocrinology, United Kingdom. He also received the titles of Officer of the Order of Canada and of the National Order of Québec.

Carreer Highlights 

Dr. Labrie isolated the first mammalian messenger RNA, namely hemoglobin mRNA, during his postdoctoral research studies in Cambridge, United Kingdom, before returning to Laval University in 1969 where he founded the Laboratory of Molecular Endocrinology, one of the largest research groups in endocrinology worldwide with a total personnel, at one time, of 350 members including 32 senior scientists.

From 1982 to 2008, he has been scientific director of the CHUL (Centre Hospitalier de l'Université Laval) Research Center (1200 employees), one of the largest medical research Institutes in Canada, with an annual budget of over $65 M. The last addition to the CHUL Research Center is the Genomic Center, thus providing genomic technology to the already unique expertise of the CHUL Research Center. From 1990 to 2002, Dr. Labrie has been head of the Department of Anatomy and Physiology at the Faculty of Medicine at Laval University.

An early and major contribution of Dr. Labrie to clinical medicine has been the discovery and development of medical castration with GnRH agonists as well as combined androgen blockade, the first treatment shown to prolong life in prostate cancer. This treatment has become the standard hormonal therapy of prostate cancer worldwide and is the basis of the success recently obtained with new blockers of androgen action (X-Tandi) and biosynthesis (Zytiga) in prostate cancer.

Following his major discovery in prostate cancer, Dr. Labrie has shown that all androgens and estrogens in women after menopause are made in peripheral tissues by the mechanisms of intracrinology from the inactive precursor dehydroepiandrosterone (DHEA) of adrenal origin. Dr. Labrie and his group also discovered the most potent antiestrogen, namely acolbifene for the prevention and treatment of breast cancer.

As CEO and CSO of EndoCeuticsTM, Dr. Labrie is pursuing the clinical development of IntrarosaTM for the treatment of sexual dysfunction. On November 16th, 2016, IntrarosaTM (intravaginal prasterone) was approved by the US FDA for commercialization in the United States. His Phase III clinical program also includes the combination of DHEA (prasterone with acolbifene for the treatment of vasomotor symptoms and prevention of breast cancer and osteoporosis/fractures as well as Alzheimer’s disease. Potent antagonists of the androgen receptor are at the stage of phase I/II trials. His clinical program also includes the treatment of endometriosis and male hypogonadism/loss of libido.


For more information about Dr Labrie, see: 

See all publications and selected presentations of Dr Fernand Labrie.